Click here to close now.




















Welcome!

News Feed Item

Spina Bifida Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spina Bifida Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

Spina Bifida Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spina Bifida Global Clinical Trials Review, H2, 2014" provides data on the Spina Bifida clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spina Bifida. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spina Bifida. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Spina Bifida 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Spina Bifida 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Tengion, Inc. 26
Clinical Trial Overview of Tengion, Inc. 26
Clinical Trial Overview of Top Institutes / Government 27
Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Centers for Disease Control and Prevention 28
Clinical Trial Overview of Centers for Disease Control and Prevention 28
William Beaumont Hospitals 29
Clinical Trial Overview of William Beaumont Hospitals 29
Aarhus University 30
Clinical Trial Overview of Aarhus University 30
Rennes University Hospital 31
Clinical Trial Overview of Rennes University Hospital 31
Baylor College of Medicine 32
Clinical Trial Overview of Baylor College of Medicine 32
UMC Utrecht Holding BV 33
Clinical Trial Overview of UMC Utrecht Holding BV 33
Universitaire Ziekenhuizen Leuven 34
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 34
University of New Mexico 35
Clinical Trial Overview of University of New Mexico 35
Duke University 36
Clinical Trial Overview of Duke University 36
Five Key Clinical Profiles 37
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Disclaimer 58
Source 58

List of Tables

Spina Bifida Therapeutics, Global, Clinical Trials by Region, 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Spina Bifida Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Spina Bifida Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Spina Bifida Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Spina Bifida Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Spina Bifida Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 25
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Tengion, Inc., 2014* 26
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 27
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 28
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by William Beaumont Hospitals, 2014* 29
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University, 2014* 30
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Rennes University Hospital, 2014* 31
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 32
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by UMC Utrecht Holding BV, 2014* 33
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 34
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by University of New Mexico, 2014* 35
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 36

List of Figures

Spina Bifida Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 57

To order this report: Spina Bifida Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
Amazon and Google have built software-defined data centers (SDDCs) that deliver massively scalable services with great efficiency. Yet, building SDDCs has proven to be a near impossibility for ‘normal’ companies without hyper-scale resources. In his session at 17th Cloud Expo, David Cauthron, founder and chief executive officer of Nimboxx, will discuss the evolution of virtualization (hardware, application, memory, storage) and how commodity / open source hyper converged infrastructure (HCI) so...
Enterprises can achieve rigorous IT security as well as improved DevOps practices and Cloud economics by taking a new, cloud-native approach to application delivery. Because the attack surface for cloud applications is dramatically different than for highly controlled data centers, a disciplined and multi-layered approach that spans all of your processes, staff, vendors and technologies is required. This may sound expensive and time consuming to achieve as you plan how to move selected applicati...
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
Contrary to mainstream media attention, the multiple possibilities of how consumer IoT will transform our everyday lives aren’t the only angle of this headline-gaining trend. There’s a huge opportunity for “industrial IoT” and “Smart Cities” to impact the world in the same capacity – especially during critical situations. For example, a community water dam that needs to release water can leverage embedded critical communications logic to alert the appropriate individuals, on the right device, as...
U.S. companies are desperately trying to recruit and hire skilled software engineers and developers, but there is simply not enough quality talent to go around. Tiempo Development is a nearshore software development company. Our headquarters are in AZ, but we are a pioneer and leader in outsourcing to Mexico, based on our three software development centers there. We have a proven process and we are experts at providing our customers with powerful solutions. We transform ideas into reality.
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...